A systematic review and meta-analysis of 27 studies also showed that SGLT-2 inhibitors reduced the risk of renal and cardiovascular disease impairment in patients with chronic kidney disease and patients with diabetes [28]. This evidence concerns the gene SLC5A2 and chronic kidney disease.